The chemical class of NBK Inhibitors represents a diverse group of compounds characterized by their ability to indirectly modulate the activity of NBK, a pro-apoptotic protein involved in apoptosis and cellular stress responses. These inhibitors operate through various signaling pathways and molecular interactions, reflecting the complex regulation of NBK in cellular processes. Compounds such as Z-VAD-FMK and Q-VD-OPh, as pan-caspase inhibitors, demonstrate the indirect approach to inhibiting NBK by targeting the broader apoptosis pathway. By inhibiting caspase activity, these compounds can reduce the apoptotic signaling cascade in which NBK plays a critical role, thereby indirectly inhibiting its pro-apoptotic function. This approach highlights the interconnected nature of apoptotic pathways and the value for modulating specific components, like NBK, through broader pathway inhibition.
Other compounds in this class, including ABT-737, SP600125, PD98059, and LY294002, showcase different mechanisms of indirect NBK inhibition. ABT-737 targets Bcl-2 family proteins, influencing the balance of pro- and anti-apoptotic signals, which can indirectly affect NBK's activity. Inhibitors of signaling pathways such as JNK, MEK, and PI3K, represented by SP600125, PD98059, LY294002, and Wortmannin, demonstrate the ability to indirectly modulate NBK activity by altering upstream signaling pathways that regulate cell death and survival processes. Additionally, compounds like 17-AAG, U0126, Rapamycin, MG132, and Sorafenib expand the scope of indirect inhibitors. 17-AAG, as an HSP90 inhibitor, affects protein folding and stability, impacting the proteins and pathways that regulate NBK's function. U0126 and Rapamycin, through their actions on the MEK/ERK and mTOR pathways, respectively, offer insights into how modulation of key signaling nodes can influence the regulation of NBK in the context of cell growth and apoptosis. In conclusion, the NBK Inhibitors class represents a strategic approach to modulating the activity of NBK through indirect means.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor that can inhibit apoptosis. By blocking caspase activity, it could indirectly inhibit NBK's pro-apoptotic function. | ||||||
Q-VD-OPH | 1135695-98-5 | sc-222230 | 5 mg | $782.00 | 5 | |
Q-VD-OPh is another broad-spectrum caspase inhibitor. Its inhibition of caspases might reduce the apoptotic signaling in which NBK is involved, indirectly inhibiting its function. | ||||||
ABT 737 | 852808-04-9 | sc-207242 | 2.5 mg | $204.00 | 54 | |
ABT-737 targets Bcl-2 family proteins. By influencing the balance of anti- and pro-apoptotic proteins, it could indirectly affect NBK's role in apoptosis. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. As JNK signaling can regulate apoptotic pathways, its inhibition might indirectly reduce NBK-mediated apoptosis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that affects the MAPK/ERK pathway. By dampening this pathway, it could indirectly influence NBK's role in cell death. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. Inhibiting PI3K/Akt signaling could indirectly reduce the pro-apoptotic function of NBK. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, another PI3K inhibitor, might similarly influence NBK activity indirectly through the PI3K/Akt pathway. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG, an HSP90 inhibitor, can disrupt protein folding and signaling pathways. This disruption might indirectly affect NBK's function in apoptosis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cell growth. Inhibiting mTOR signaling might indirectly reduce NBK's apoptotic activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor. By affecting protein degradation pathways, it might indirectly modulate NBK's role in apoptosis. | ||||||